<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554914</url>
  </required_header>
  <id_info>
    <org_study_id>ATA129-EBV-205</org_study_id>
    <secondary_id>2020-000177-25</secondary_id>
    <nct_id>NCT04554914</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases</brief_title>
  <official_title>An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atara Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atara Biotherapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of tabelecleucel in&#xD;
      participants with Epstein-Barr virus (EBV) associated diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, multicohort, open label, single-arm, Phase 2 study to assess the&#xD;
      efficacy and safety of tabelecleucel for the treatment of EBV-associated diseases in&#xD;
      participants who are newly diagnosed or relapsed/refractory to prior treatment. Newly&#xD;
      diagnosed or relapsed/refractory participants will be enrolled in one of the following&#xD;
      cohorts:&#xD;
&#xD;
        -  EBV+ lymphoproliferative disease (LPD) in the setting of primary immunodeficiency (PID)&#xD;
           (PID LPD)&#xD;
&#xD;
        -  EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency (AID) (AID LPD)&#xD;
&#xD;
        -  EBV+ posttransplant lymphoproliferative disorder involving the central nervous system&#xD;
           (CNS PTLD)&#xD;
&#xD;
        -  EBV+ PTLD where standard first line therapy (rituximab or chemotherapy) is not&#xD;
           appropriate, including CD20 negative disease&#xD;
&#xD;
        -  EBV+ sarcomas, including leiomyosarcoma (LMS)&#xD;
&#xD;
        -  Chronic active EBV (CAEBV) and EBV+ hemophagocytic lymphohistiocytosis (HLH) (CAEBV/HLH&#xD;
           cohort)&#xD;
&#xD;
      Tabelecleucel will be administered in cycles lasting for 35 days. During each cycle,&#xD;
      participants will receive tabelecleucel at a dose of 2 x 10^6 cells/kg intravenously (IV)&#xD;
      weekly for 3 weeks, followed by observation through Day 35. Treatment will continue until&#xD;
      maximal disease progression, unacceptable toxicity, or initiation of nonprotocol therapy for&#xD;
      the underlying disease. For EBV+ sarcoma cohort, treatment will continue until disease&#xD;
      progression, unacceptable toxicity, or up to 24 months from first dose. Participants who fail&#xD;
      to respond to initial tabelecleucel treatment may continue tabelecleucel with a different&#xD;
      human leukocyte antigen (HLA) restriction (termed a Restriction Switch), if available;&#xD;
      administration of tabelecleucel with up to 4 different HLA restrictions is allowed for any&#xD;
      participant.&#xD;
&#xD;
      Participants will complete a safety follow-up visit at 30 days after the last dose.&#xD;
      Participants without documented disease progression will be assessed every 3 months after the&#xD;
      safety follow-up visit for continued evaluation of disease response until the end of study&#xD;
      (EOS) visit at 24-month after first dose. Participants with disease progression any time&#xD;
      prior to the EOS visit will continue to be followed every 3 months for survival status until&#xD;
      the EOS visit.&#xD;
&#xD;
      An adaptive 2-stage design will be used for each cohort in this study. For each cohort,&#xD;
      approximately 8 participants will be enrolled in Stage 1. The decision to move to Stage 2&#xD;
      enrollment will be based on an interim analysis of the first 8 evaluable participants in the&#xD;
      cohort using investigator's assessment (per defined radiologic, clinical, and/or laboratory&#xD;
      response criteria). The number of participants enrolled in Stage 2 for each cohort will&#xD;
      depend on the number of observed responders in Stage 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">May 2029</completion_date>
  <primary_completion_date type="Anticipated">June 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For EBV+ PID LPD and CAEBV/HLH cohorts who are eligible for allogeneic HCT: Number of participants who reach definitive therapy (ie, allogeneic HCT) for the underlying disease</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For EBV+ PID LPD and CAEBV/HLH cohorts who are eligible for allogeneic HCT: Time to allogeneic HCT</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For EBV+ sarcomas, including LMS: Clinical benefit rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For EBV+ sarcomas, including LMS: ORR by immune response evaluation criteria in solid tumors (iRECIST) criteria</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Epstein-Barr Virus (EBV)-Associated Diseases</condition>
  <condition>EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (PID LPD)</condition>
  <condition>EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (AID LPD)</condition>
  <condition>EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (CNS PTLD)</condition>
  <condition>EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)</condition>
  <condition>Solid Organ Transplant Complications</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <condition>Allogeneic Hematopoietic Cell Transplant</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <condition>EBV+ Sarcomas</condition>
  <condition>Leiomyosarcoma</condition>
  <condition>Chronic Active Epstein-Barr Virus (CAEBV)</condition>
  <condition>Chronic Active Epstein-Barr Virus With Hemophagocytic Lymphohistiocytosis (HLH)</condition>
  <condition>Lymphohistiocytosis, Hemophagocytic</condition>
  <arm_group>
    <arm_group_label>EBV+ PID LPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with newly diagnosed or relapsed/refractory EBV+ PID LPD will receive IV tabelecleucel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBV+ AID LPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with newly diagnosed or relapsed/refractory EBV+ AID LPD will receive IV tabelecleucel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBV+ PTLD CNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with newly diagnosed or relapsed/refractory EBV+ PTLD CNS will receive IV tabelecleucel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBV+ PTLD (ineligible for first-line therapy or CD20 negative)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with EBV+ PTLD where standard first line therapy (rituximab or chemotherapy) is not appropriate, including CD20 negative disease will receive IV tabelecleucel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBV+ sarcoma, including LMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with newly diagnosed or failed systemic first-line therapy for EBV+ sarcoma will receive IV tabelecleucel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAEBV/ HLH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with newly diagnosed or previously treated CAEBV or EBV viremia with HLH will receive IV tabelecleucel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tabelecleucel</intervention_name>
    <description>Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.</description>
    <arm_group_label>CAEBV/ HLH</arm_group_label>
    <arm_group_label>EBV+ AID LPD</arm_group_label>
    <arm_group_label>EBV+ PID LPD</arm_group_label>
    <arm_group_label>EBV+ PTLD (ineligible for first-line therapy or CD20 negative)</arm_group_label>
    <arm_group_label>EBV+ PTLD CNS</arm_group_label>
    <arm_group_label>EBV+ sarcoma, including LMS</arm_group_label>
    <other_name>tab-cel®</other_name>
    <other_name>ATA129</other_name>
    <other_name>EBV-CTLs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of EBV+ disorder&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status &lt;= 3 for participants aged &gt;= 16&#xD;
             years; Lansky score &gt;= 20 for participants from 1 year to &lt; 16 years&#xD;
&#xD;
          -  Adequate organ function test results, unless organ dysfunction is considered to be due&#xD;
             to the underlying EBV-associated disease by the investigator&#xD;
&#xD;
        Cohort-specific Inclusion Criteria:&#xD;
&#xD;
          -  For participants with PID LPD:&#xD;
&#xD;
               -  Newly diagnosed or relapsed/refractory LPD confirmed by biopsy-proven EBV+ LPD or&#xD;
                  positive cerebrospinal fluid (CSF) cytology with or without radiographically&#xD;
                  measurable intracranial disease with EBV detected in CSF&#xD;
&#xD;
               -  Participant must have systemic measurable disease and/ or CNS measurable disease&#xD;
&#xD;
               -  Definitive therapy (eg, allogeneic HCT, gene therapy) for the underlying PID is&#xD;
                  planned&#xD;
&#xD;
               -  Participants with newly diagnosed disease should be ineligible for standard&#xD;
                  first-line therapy for EBV+ LPD, as determined by the investigator&#xD;
&#xD;
          -  For participants with AID LPD:&#xD;
&#xD;
               -  Newly diagnosed or relapsed/refractory LPD confirmed by biopsy-proven EBV+ LPD or&#xD;
                  positive CSF cytology, with or without radiographically measurable intracranial&#xD;
                  disease, with EBV detected in CSF&#xD;
&#xD;
               -  Participant must have systemic measurable disease and/ or CNS measurable disease&#xD;
&#xD;
               -  Participants who are human immunodeficiency virus positive (HIV+) must meet both&#xD;
                  of the following criteria: Have an HIV viral load assessed by reverse&#xD;
                  transcription-polymerase chain reaction (RT-PCR) below the lower limit of&#xD;
                  detection and CD4 &gt;= 50 cells/μL within 6 months prior to the first dose of&#xD;
                  tabelecleucel&#xD;
&#xD;
               -  Participants with newly diagnosed disease should be ineligible for standard&#xD;
                  first-line therapy for EBV+ LPD, as determined by the investigator&#xD;
&#xD;
          -  For participants with CNS PTLD:&#xD;
&#xD;
               -  Newly diagnosed or relapsed/refractory EBV+ CNS PTLD histologically confirmed by&#xD;
                  biopsy-proven EBV+ CNS PTLD or positive CSF cytology with or without&#xD;
                  radiographically measurable intracranial disease with EBV detected in CSF&#xD;
&#xD;
               -  Participant may have systemic and CNS disease or CNS disease only&#xD;
&#xD;
               -  Participants with newly diagnosed disease should be ineligible for standard&#xD;
                  first-line therapy for EBV+ LPD, as determined by the investigator&#xD;
&#xD;
          -  For participants with EBV+ PTLD, where standard first line therapy (rituximab and/or&#xD;
             chemotherapy) is not appropriate, including CD20-negative disease:&#xD;
&#xD;
               -  Newly diagnosed, biopsy-proven EBV+ PTLD&#xD;
&#xD;
               -  Ineligible for standard first-line therapy for EBV+ PTLD, as determined by the&#xD;
                  investigator&#xD;
&#xD;
               -  Participants must have systemic disease measurable per Lugano Classification&#xD;
                  criteria, except when contraindicated or mandated by local practice, then MRI may&#xD;
                  be used.&#xD;
&#xD;
          -  For participants with sarcoma, including LMS:&#xD;
&#xD;
               -  Newly diagnosed or failed systemic first-line therapy for EBV+ sarcoma.&#xD;
                  Participants with newly diagnosed disease should be ineligible for standard&#xD;
                  first-line therapy for EBV+ sarcoma, as determined by the investigator.&#xD;
&#xD;
               -  Biopsy-proven EBV+ sarcoma&#xD;
&#xD;
               -  Measurable disease using diagnostic PET/CT and/or MRI following RECIST 1.1&#xD;
                  criteria&#xD;
&#xD;
          -  For participants with CAEBV:&#xD;
&#xD;
               -  Newly diagnosed or previously treated CAEBV&#xD;
&#xD;
               -  Detectable EBV viremia on at least 2 occasions at a minimum of 90 days apart&#xD;
&#xD;
               -  At least 3 active clinical findings (per Kimura H, et al. Front Immunol.&#xD;
                  2017;8:1867) as: Fever &gt;= 38.5°C; splenomegaly, lymphadenopathy, and/or&#xD;
                  hepatomegaly; cytopenia affecting at least 2 or 3 lineages in the peripheral&#xD;
                  blood (hemoglobin &lt; 9 g/dL, platelets &lt; 100 × 10^3/mL, neutrophils &lt; 1 ×&#xD;
                  10^3/mL); hypogammaglobulinemia; hemophagocytosis; hepatitis; neuropathy; rash;&#xD;
                  and hydroa vacciniforme&#xD;
&#xD;
          -  For participants with EBV+ viremia with HLH:&#xD;
&#xD;
               -  Newly diagnosed or previously treated EBV+ viremia with HLH&#xD;
&#xD;
               -  A molecular diagnosis consistent with HLH-2004 trial (per Henter JI, et al.&#xD;
                  Pediatr Blood Cancer. 2007;48:124-31) OR 5 or more of the clinical symptoms (per&#xD;
                  Jordan MB, et al. Blood. 2011;118:4041-4052): Fever &gt;= 38.5°C; splenomegaly;&#xD;
                  cytopenia affecting at least 2 or 3 lineages in the peripheral blood (hemoglobin&#xD;
                  &lt; 9 g/dL, platelets &lt; 100 × 10^3/mL, neutrophils &lt; 1 × 10^3/mL);&#xD;
                  hypertriglyceridemia (fasting &gt;= 265 mg/dL) and/or hypofibrinogenemia (&lt;= 150&#xD;
                  mg/dL); hemophagocytosis in bone marrow, spleen, lymph nodes, or liver; low or&#xD;
                  absent natural killer cell (NK-cell) activity; ferritin &gt;= 500 ng/mL; and&#xD;
                  elevated soluble CD25&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Burkitt, T-cell (except in the setting of HLH), natural killer/T-cell lymphoma/LPD,&#xD;
             Hodgkin, or transformed lymphoma&#xD;
&#xD;
          -  Serious known active infections, defined as ongoing uncontrolled adenovirus infection&#xD;
             or infections requiring systemic therapy at the time of enrollment&#xD;
&#xD;
          -  Suspected or confirmed Grade &gt;= 2 acute graft-versus-host disease (GvHD) per the&#xD;
             Center for International Blood and Marrow Transplant Research (CIBMTR) consensus&#xD;
             grading system or extensive chronic GvHD per National Institutes of Health (NIH)&#xD;
             consensus criteria at the time of the enrollment&#xD;
&#xD;
          -  Need for vasopressor or ventilatory support&#xD;
&#xD;
          -  Prior therapy (in order of increasing washout period) prior to enrollment as:&#xD;
&#xD;
               -  Within 4 weeks or 5 half-lives (whichever is shorter) for any investigational&#xD;
                  product and/ or any chemotherapy (systemic or intrathecal), targeted small&#xD;
                  molecule therapy, or antibody/biologic therapy. Note: prior anti-CD20 antibody&#xD;
                  use is permitted within the washout period if a subsequent disease response&#xD;
                  assessment indicates disease progression&#xD;
&#xD;
               -  Within &lt;= 8 weeks for cellular therapies (EBV-CTLs, chimeric antigen receptor&#xD;
                  therapies directed at T cells or T-cell subsets, donor lymphocyte infusion, other&#xD;
                  CTLs); and/or therapies which could impact tabelecleucel function (anti-thymocyte&#xD;
                  globulin, alemtuzumab)&#xD;
&#xD;
          -  Unwilling to use protocol specified contraceptive methods&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Ongoing need for daily steroids of &gt; 0.5 mg/kg prednisone or glucocorticoid&#xD;
             equivalent, ongoing methotrexate, or extracorporeal photopheresis (protocol-specified&#xD;
             dexamethasone is permitted and concludes by the time of enrollment)&#xD;
&#xD;
          -  For participants with PID LPD or AID LPD: history of prior allogeneic HCT or solid&#xD;
             organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Faith Galderisi, DO</last_name>
    <role>Study Director</role>
    <affiliation>Atara Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>650-278-8930</phone>
    <phone_ext>option 1</phone_ext>
    <email>clinicalstudies@atarabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Orange County (Pediatrics [up to 25 years old])</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilibeth Torno, MD</last_name>
      <phone>714-509-4348</phone>
      <email>ltorno@choc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center (Adults and Pediatrics)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehrdad Abedi, MD</last_name>
      <phone>916-734-3772</phone>
      <email>mabedi@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute (Adults [&gt;= 16 years])</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Koff, MD</last_name>
      <phone>404-778-3942</phone>
      <email>jkoff@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago (Pediatrics only)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonali Chaudhury, MD</last_name>
      <phone>312-227-4090</phone>
      <email>schaudhury@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center (Adults only)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saurabh Dahiya, MD</last_name>
      <phone>330-518-9022</phone>
      <email>sdahiya@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute (DFCI) (Adults and Pediatrics)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Nikiforow, MD</last_name>
      <phone>617-632-3477</phone>
      <email>sarah_nikiforow@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Rogel Cancer Center (Adults and Pediatrics)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monalisa Ghosh, MD</last_name>
      <phone>734-232-4484</phone>
      <email>ghoshm@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis (Adults only)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Ghobadi, MD</last_name>
      <phone>314-747-2743</phone>
      <email>arminghobadi@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore (Adults and Pediatrics)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Loeb, MD</last_name>
      <phone>718-920-4664</phone>
      <email>david.loeb@einsteinmed.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center (Adults only)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ran Reshef, MD</last_name>
      <phone>212-342-0530</phone>
      <email>ran.reshef@columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center (Adults and Pediatrics)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepa Jagadeesh,, MD</last_name>
      <phone>216-444-0857</phone>
      <email>jagaded@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (Adults and Pediatrics)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Hudspeth, MD</last_name>
      <phone>843-792-0381</phone>
      <email>hudspeth@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center (Pediatrics only)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Aquino, MD</last_name>
      <phone>214-648-8800</phone>
      <email>victor.aquino@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson (Adults and Pediatrics)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Mahadeo,, MD</last_name>
      <phone>713-792-2873</phone>
      <email>KMMahadeo@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz (Adults only)</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hildegard Greinix, MD</last_name>
      <phone>43 3 163 858 4086</phone>
      <email>hildegard.greinix@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Salzburg Landeskrankenhaus (Adults only)</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Greil, MD</last_name>
      <phone>43(0) 57 2550</phone>
      <email>r.greil@salk.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien (Adults only)</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Worel, MD</last_name>
      <phone>43 01 40 400 5302</phone>
      <email>nina.worel@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan (Adults only)</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Snauwaert, MD</last_name>
      <phone>32 50-45-21-11</phone>
      <email>sylvia.snauwaert@azsintjan.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Delta - Campus Rumbeke (Adults only)</name>
      <address>
        <city>Roeselare</city>
        <state>West-Vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dries Deeran, MD</last_name>
      <phone>32 51 23 76 56</phone>
      <email>dries.deeren@azdelta.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Eloi (Adults and Pediatrics)</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Herbaux, MD</last_name>
      <phone>+33 4 67 33 67 33</phone>
      <email>c-herbaux@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Pitié Salpêtrière (Adults only)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain S Choquet, MD</last_name>
      <phone>+33 1 42 16 28 26</phone>
      <email>sylvain.choquet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades (Adults and Pediatrics)</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Suarez, MD</last_name>
      <phone>33 1 44 49 52 87</phone>
      <email>felipe.suarez@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù (Adults and Pediatrics)</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli, MD</last_name>
      <phone>39 06 68592129</phone>
      <email>franco.locatelli@opbg.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita (Pediatrics only)</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD</last_name>
      <phone>39 01 13135230</phone>
      <email>franca.fagioli@unito.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón (Adults and Pediatrics)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Barba Suñol, MD</last_name>
      <phone>34 934893806</phone>
      <email>pbarba@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal (Adults only)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier López Jiménez, MD</last_name>
      <phone>34 91-336-80-00</phone>
      <email>jlopezj.hrc@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Viegen del Rocio (Adults and Pediatrics)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Antonio Perez Simon, MD</last_name>
      <phone>+34 9 55 01 31 61</phone>
      <email>josea.perez.simon.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic, Off-The-Shelf T-cell Immunotherapy</keyword>
  <keyword>Epstein-Barr Virus (EBV)</keyword>
  <keyword>Epstein-Barr Virus-specific Cytotoxic T lymphocyte (EBV-CTL)</keyword>
  <keyword>Solid Organ Transplant (SOT)</keyword>
  <keyword>Hematopoietic Cell Transplant (HCT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

